If you’re trying to understand how the Australian sharemarket values businesses and allocates capital across the global economy, 4DMedical would not be a good place to start.
It’s a company that has delivered more than many, in terms of shareholder returns in the major sharemarket index but at the same time, it’s a favourite among hedge funds to short while institutions and retail investors are in disagreement about whether it’s appropriately governed.
Gift articles to anyone you choose each month when you subscribe.
